Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Study Type: Phase III Randomized Trial
Population: HR+/HER2- Advanced Breast Cancer
N: 726 Patients (2:1 Randomization)
DOI:

Study Design & Arms

Baseline Quality of Life Scores (Mean ± SD)

Table 1

Hazard Ratios for Time to Deterioration (TTD ≥10%)

Abstract / Results

Risk Reduction (1 - HR) for Deterioration

Derived from HR

Patient Population (2:1 Randomization)

Methods

Metric Significance Overview

Appendix: Raw Data & Provenance

ID Metric Group Value Source
Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode